Japanese firm acquires US drugmaker after increasing offer

25-10-2022

Staff Writer

Japanese firm acquires US drugmaker after increasing offer

HENADZI KlLENT / Shutterstock.com

The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.


Sumitomo Pharma, Myovant, Sumitovant Biopharma, M&A, mergers and acquisitions, women’s health, oncology

LSIPR